BTIG Research Reiterates Neutral Rating for Poseida Therapeutics (NASDAQ:PSTX)

BTIG Research reissued their neutral rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a report issued on Tuesday, Marketbeat reports.

Several other analysts have also commented on the stock. HC Wainwright restated a “neutral” rating and issued a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a report on Tuesday. William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.50.

Poseida Therapeutics Trading Down 0.2 %

NASDAQ:PSTX opened at $9.31 on Tuesday. The company has a 50-day moving average price of $3.25 and a 200-day moving average price of $3.10. The stock has a market cap of $907.35 million, a price-to-earnings ratio of -14.78 and a beta of 0.54. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. Poseida Therapeutics has a 12 month low of $1.87 and a 12 month high of $9.42.

Insiders Place Their Bets

In other news, Chairman Mark J. Gergen sold 30,000 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total transaction of $278,100.00. Following the transaction, the chairman now directly owns 651,291 shares of the company’s stock, valued at $6,037,467.57. This represents a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Poseida Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Bayesian Capital Management LP bought a new position in shares of Poseida Therapeutics in the first quarter worth approximately $33,000. Marshall Wace LLP bought a new stake in Poseida Therapeutics during the second quarter valued at about $31,000. Rothschild Investment LLC purchased a new position in shares of Poseida Therapeutics in the second quarter valued at about $35,000. Principal Financial Group Inc. bought a new position in shares of Poseida Therapeutics in the second quarter worth about $35,000. Finally, Virtu Financial LLC purchased a new stake in shares of Poseida Therapeutics during the third quarter worth about $37,000. 46.87% of the stock is currently owned by hedge funds and other institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.